Combination of vaccinium uliginosum extract and corn stigma extract

Abstract

Disclosed is a combination of a vaccinium uliginosum extract and a corn stigma extract.

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This patent application claims the benefit of priority based on Japanese Patent Application No. 2022-202400 (filing date: December 19, 2022), a Japanese patent application based on a prior application. The entire disclosure of the prior patent application is incorporated herein by reference as part of this specification. TECHNICAL FIELD

[0003] The present invention relates to a combination of Vaccinium uliginosum extract and corn silk extract. BACKGROUND ART

[0004] Proteins play various physiological roles in living organisms. However, in living organisms, a reaction called the Maillard reaction or glycation reaction occurs in which proteins and amino acids in tissues are glycated, and in some cases, abnormal proteins may be formed and accumulate in the body. For example, when the metabolic function decreases due to aging or when hyperglycemia persists due to the onset of diabetes, the glycation reaction gradually progresses in living organisms, and the normal functions of proteins in various tissues are impaired. It is known that if the glycation reaction occurs, an irreversible compound called advanced glycation end-products (AGEs) is ultimately formed, deposited in various tissues, or binds to AGE receptors locally present in vascular endothelial cells, thereby causing various diseases.

[0005] As diseases in which glycation of proteins is considered to be one of the factors contributing to the onset, diabetes complications, kidney disease, retinopathy, nerve damage, Alzheimer's disease, arteriosclerosis, malignant tumors, bone diseases, neurodegenerative diseases, etc. are known. In addition, glycation of proteins is also considered to be one of the factors contributing to skin aging.

[0006] Furthermore, in food and drink products containing proteins and sugars, for example, problems such as browning and precipitation of food and drink products due to the glycation reaction occur during storage. Therefore, it is considered effective to inhibit protein glycation for the prevention / treatment of these diseases and symptoms and to prevent food and drink products from denaturing during storage, and various studies have been conducted so far.

[0007] For example, Patent Document 1 discloses a glycation reaction inhibitor containing one or more plants selected from the group consisting of Petasites japonicus, Castanea crenata, Arachis hypogaea, Diospyros kaki, Rosa canina, Vaccinium corymbosum, Punica granatum, Rosmarinus officinalis, Vitis vinifera, Prunus armeniaca, Perilla frutescens, Salvia japonica, Mentha canadensis, Satureja hortensis, Ilex paraguariensis, Coffea arabica, Olea europaea, and Camellia sinensis or processed products thereof.

[0008] Thus, as glycation inhibitors, a variety of active ingredients have been discovered, but their effects are not necessarily sufficient, and currently, glycation inhibitors with higher effects are being sought.

[0009] Prior art documents

[0010] Patent documents

[0011] Patent Document 1: Japanese Unexamined Patent Application Publication No. 2015-160842 Summary of the Invention

[0012] The present inventors newly discovered a combination of Vaccinium uliginosum extract and corn silk extract. The present invention is based on this finding.

[0013] Accordingly, the present invention provides a combination of Vaccinium uliginosum extract and corn silk extract.

[0014] According to the present invention, the following inventions are provided.

[0015] (1) A composition comprising a Vaccinium uliginosum extract, wherein the Vaccinium uliginosum extract is used in combination with a composition comprising a corn silk extract.

[0016] (2) A composition comprising a corn silk extract, wherein the corn silk extract is used in combination with a composition comprising a Vaccinium uliginosum extract.

[0017] (3) A composition comprising a Vaccinium uliginosum extract and a corn silk extract.

[0018] (4) The composition according to any one of (1) to (3), which is used for inhibiting glycation.

[0019] (5) The composition according to any one of (1) to (4), which is used for inhibiting skin glycation.

[0020] (6) The composition according to any one of (1) to (5), which is used for preventing or improving one or more selected from the group consisting of firmness, wrinkles, and sagging.

[0021] (7) The composition according to any one of (1) to (6), which is used such that CA / CB is 0.15 to 7.5, wherein CA is the dry weight of the corn silk extract and CB is the dry weight of the Vaccinium uliginosum extract.

[0022] (8) The composition according to any one of (1) to (7), which is an oral composition.

[0023] (9) A combination of Vaccinium uliginosum extract and corn silk extract.

[0024] (10) Use of a combination of Vaccinium uliginosum extract and corn silk extract in the manufacture of a medicament for the purpose of inhibiting glycation.

[0025] (11) Use of a combination of Vaccinium uliginosum extract and corn silk extract in the manufacture of a medicament for the purpose of inhibiting skin glycation.

[0026] (12) Use of a combination of Vaccinium uliginosum extract and corn silk extract in the manufacture of a medicament for the purpose of preventing or improving one or more selected from the group consisting of firmness, wrinkles, and sagging.

[0027] (13) The use according to any one of (10) to (12), which is used in such a manner that CA / CB becomes 0.15 to 7.5, wherein the dry weight of the corn silk extract is designated as CA and the dry weight of the Vaccinium uliginosum extract is designated as CB.

[0028] (14) The use according to any one of (10) to (13), wherein the Vaccinium uliginosum extract or the corn silk extract is in the form of an oral composition.

[0029] (15) Use of a combination of Vaccinium uliginosum extract and corn silk extract in inhibiting glycation.

[0030] (16) Use of a combination of Vaccinium uliginosum extract and corn silk extract in inhibiting skin glycation.

[0031] (17) Use of a combination of Vaccinium uliginosum extract and corn silk extract in preventing or improving one or more selected from the group consisting of firmness, wrinkles, and sagging.

[0032] (18) The use according to any one of (15) to (17), which is used in such a manner that CA / CB becomes 0.15 to 7.5, wherein the dry weight of the corn silk extract is designated as CA and the dry weight of the Vaccinium uliginosum extract is designated as CB.

[0033] (19) The use according to any one of (15) to (18), wherein the Vaccinium uliginosum extract or the corn silk extract is in the form of an oral composition.

[0034] (20) A combination of Vaccinium uliginosum extract and corn silk extract for inhibiting glycation.

[0035] (21) A combination of Vaccinium uliginosum extract and corn silk extract for inhibiting skin glycation.

[0036] (22) A combination of Vaccinium uliginosum extract and corn silk extract for preventing or improving one or more selected from the group consisting of firmness, wrinkles, and sagging.

[0037] (23) The combination of the Vaccinium uliginosum extract and the corn silk extract according to any one of (20) to (22) is used in such a manner that CA / CB becomes 0.15 to 7.5, wherein the dry weight of the corn silk extract is designated as CA and the dry weight of the Vaccinium uliginosum extract is designated as CB.

[0038] (24) The combination of the Vaccinium uliginosum extract and the corn silk extract according to any one of (20) to (23), wherein the Vaccinium uliginosum extract or the corn silk extract is in the form of an oral composition.

[0039] (25) A method for inhibiting glycation in a subject, the method comprising the step of administering an effective amount of a combination formed by the Vaccinium uliginosum extract and the corn silk extract.

[0040] (26) A method for inhibiting skin glycation in a subject, the method comprising the step of administering an effective amount of a combination formed by the Vaccinium uliginosum extract and the corn silk extract.

[0041] (27) A method for preventing or improving one or more selected from the group consisting of firmness, wrinkles, and sagging in a subject, the method comprising the step of administering an effective amount of a combination formed by the Vaccinium uliginosum extract and the corn silk extract.

[0042] (28) The method according to any one of (25) to (27), which is administered in such a manner that CA / CB becomes 0.15 to 7.5, wherein the dry weight of the corn silk extract is designated as CA and the dry weight of the Vaccinium uliginosum extract is designated as CB.

[0043] (29) The method according to any one of (25) to (28), wherein the Vaccinium uliginosum extract or the corn silk extract is in the form of an oral composition.

[0044] According to the present invention, a combination of the Vaccinium uliginosum extract and the corn silk extract is provided. By using the combination of the present invention, the glycation reaction can also be effectively inhibited. BRIEF DESCRIPTION OF THE DRAWINGS

[0045] Figure 1 A graph showing the results of evaluating the anti-glycation effect after separately adding the Vaccinium uliginosum extract or the corn silk extract and after 28 days.

[0046] Figure 2 A graph showing the results of evaluating the anti-glycation effect after separately adding the Vaccinium uliginosum extract or the corn silk extract and after 35 days. DETAILED DESCRIPTION

[0047] According to one aspect of the present invention, there is provided Vaccinium uliginosum extract for use in combination with corn silk extract. It may be a composition containing Vaccinium uliginosum extract for use in combination with corn silk extract, it may be Vaccinium uliginosum extract for use in combination with a composition containing corn silk extract, or it may be a composition containing Vaccinium uliginosum extract for use in combination with a composition containing corn silk extract.

[0048] According to another aspect of the present invention, there is provided corn silk extract for use in combination with Vaccinium uliginosum extract. It may be a composition containing corn silk extract for use in combination with Vaccinium uliginosum extract, it may be corn silk extract for use in combination with a composition containing Vaccinium uliginosum extract, or it may be a composition containing corn silk extract for use in combination with a composition containing Vaccinium uliginosum extract.

[0049] According to still another aspect of the present invention, there is provided a composition containing Vaccinium uliginosum extract and corn silk extract.

[0050] According to another aspect of the present invention, there is provided a composition containing a glycation inhibitor of Vaccinium uliginosum extract for use in combination with corn silk extract or a composition containing corn silk extract. Such a composition containing a glycation inhibitor of Vaccinium uliginosum extract may be a composition containing Vaccinium uliginosum extract for inhibiting glycation.

[0051] According to another aspect of the present invention, there is provided a composition containing a glycation inhibitor of corn silk extract for use in combination with Vaccinium uliginosum extract or a composition containing Vaccinium uliginosum extract. Such a composition containing a glycation inhibitor of corn silk extract may be a composition containing corn silk extract for inhibiting glycation.

[0052] According to still another aspect of the present invention, there is provided a composition containing a glycation inhibitor of Vaccinium uliginosum extract and corn silk extract. Such a composition containing a glycation inhibitor of Vaccinium uliginosum extract and corn silk extract may be a composition containing Vaccinium uliginosum extract and corn silk extract for inhibiting glycation.

[0053] The inhibition of glycation in the present invention can be carried out either in vivo or in vitro.

[0054] As for the inhibition of glycation in vivo in the present invention, there is no limitation as long as it is the glycation of components such as proteins and amino acids in tissues, but preferably it is the inhibition of skin glycation. There is no limitation on the object for which such glycation inhibition is carried out. For example, mammals such as primates including humans and chimpanzees, pet animals such as dogs and cats, livestock animals such as cows, horses, sheep, and goats, and rodents such as mice and rats can be cited.

[0055] For the inhibition of glycation in vitro in the present invention, there is no limitation. For example, the inhibition of glycation in biological samples such as tissue sections and cells derived from organisms can be cited. Such biological samples are not limited, and those preferably derived from the skin can be used as long as they are commercially available. In addition, such biological samples are not limited, and for example, they also include biological samples that can be indirectly obtained from organisms, such as cells after cell line establishment. In addition, the inhibition of glycation in vitro in the present invention can also be carried out in substances other than biological samples. For example, the glycation of components contained in foods and beverages (such as amino acids, proteins (such as collagen, etc.)) can be inhibited.

[0056] According to a preferred embodiment of the present invention, there is provided a preventive or ameliorating agent for one or more selected from the group consisting of Firmness, Wrinkle, and Sagging, which contains Vaccinium uliginosum extract and is used in combination with corn silk extract or a composition containing corn silk extract. Such a preventive or ameliorating agent containing Vaccinium uliginosum extract can be a composition containing Vaccinium uliginosum extract for preventing or ameliorating one or more selected from the group consisting of Firmness, Wrinkle, and Sagging. In addition, such prevention or amelioration can be achieved by inhibiting glycation, but is not limited thereto.

[0057] According to another preferred embodiment of the present invention, there is provided a preventive or ameliorating agent for one or more selected from the group consisting of Firmness, Wrinkle, and Sagging, which contains corn silk extract and is used in combination with Vaccinium uliginosum extract or a composition containing Vaccinium uliginosum extract. Such a preventive or ameliorating agent containing corn silk extract can be a composition containing corn silk extract for preventing or ameliorating one or more selected from the group consisting of Firmness, Wrinkle, and Sagging. In addition, such prevention or amelioration can be achieved by inhibiting glycation, but is not limited thereto.

[0058] According to still another preferred embodiment of the present invention, there is provided a preventive or ameliorating agent for one or more selected from the group consisting of Firmness, Wrinkle, and Sagging, which contains Vaccinium uliginosum extract and corn silk extract. Such a preventive or ameliorating agent containing Vaccinium uliginosum extract and corn silk extract can be a composition containing Vaccinium uliginosum extract and corn silk extract for preventing or ameliorating one or more selected from the group consisting of Firmness, Wrinkle, and Sagging. In addition, such prevention or amelioration can be achieved by inhibiting glycation, but is not limited thereto.

[0059] The "Vaccinium uliginosum" of the present invention refers to "Vaccinium uliginosum" which is a plant belonging to the genus Vaccinium of the family Ericaceae. As a common name, it is sometimes also called bog bilberry or great bilberry. Additionally, in Japan, it is sometimes called Asama grapes or alpine grapes. As the utilization part, the whole or a part thereof can be utilized, and there is no limitation. For example, the fruit can be used. The fruit juice derived from the Vaccinium uliginosum is sometimes marked in English as Wild blueberry juice concentrate (Vaccinium uliginosum), and sometimes marked in Chinese as

[0060] Concentrated blueberry juice

[0061] The "corn silk" of the present invention refers to the substance obtained by drying the styles and stigmas of the female flowers of Zea mays L. of the family Gramineae, and is sometimes also considered as the crude drug Nanmanmao or the hair of Nanman. In China, it is sometimes used under the names of "maize stigma", "maize stamen", and "corn silk", and in Japan, it is sometimes sold under the names of "the hair of Nanman" and "Nanmanmao". The styles and stigmas of the female flowers of corn can be pulled out and dried. As the drying method, there is no limitation. For example, hot air drying, vacuum freeze drying, far infrared drying, microwave heating drying, sun drying, etc. can be cited. The above-mentioned Zea mays L. of the family Gramineae can also be its related species or cultivated varieties.

[0062] There is no particular limitation on the method for manufacturing the extract of the foregoing components, and extraction can be carried out according to the methods commonly used in this technical field. As the foregoing extraction method, there is no limitation. For example, hot water extraction method, ultrasonic extraction method, filtration method, reflux extraction method, solvent (such as ethanol) extraction method, etc. can be cited. They can be carried out alone or in combination of two or more methods. Additionally, in order to obtain a high-purity extract, the extract can be further extracted one or more times each by the same method. Additionally, as the method for manufacturing the raw material without extraction, fruit juice extraction and concentration can be cited, and it can be manufactured by any method.

[0063] There is no particular limitation on the type of extraction solvent used for manufacturing the Vaccinium uliginosum extract or corn silk extract in the present invention, as long as an extract having the object effect of the present invention is obtained, and any solvent well-known in this technical field can be used. As examples of such solvents, there is no limitation. For example, water, alcohols having 1 to 4 carbon atoms, ethyl acetate, acetone, chloroform, etc. can be cited, and two or more of them can be used in combination.

[0064] When Vaccinium uliginosum extract or corn silk extract is commercially available, it can be used as long as an extract having the object effect of the present invention is obtained. As the Vaccinium uliginosum extract, for example, Vaccinium uliginosum fruit juice (manufactured by Shangzhi Lvye Berry Co., Ltd., Heilongjiang Province) can be used.

[0065] As the corn silk extract, for example, a dried corn silk extract (manufactured by Fukudaryu Co., Ltd.) can be used. It can be manufactured as follows: After the corn silk is extracted with hot water, the moisture is dispersed and powdered, etc., whereby it can be manufactured.

[0066] The amounts of the Vaccinium uliginosum extract and the corn silk extract in the composition of the present invention can be appropriately determined according to the use. However, preferably, when the dry weight of the corn silk extract is CA and the dry weight of the Vaccinium uliginosum extract is CB, CA / CB is 0.15 to 7.5, and more preferably CA / CB is 0.3 to 3.2. The value of the dry weight in the present invention is not limited. For example, it can be obtained by directly measuring the sufficiently dried extract, or by converting the Brix of the extract (weight of soluble solids per 100 g of the extract). The conversion from Brix to dry weight can be carried out using the following formula 1.

[0067] [Mathematical formula 1]

[0068] Formula 1: [Dry weight] = [Weight of the extract] × [Brix of the extract (weight percentage)]

[0069] For example, the dry weight of 100 g of an extract with Brix 60 can be obtained as 100×60 / 100 = 60 g.

[0070] The composition of the present invention is not limited and can be any of a pharmaceutical composition, a cosmetic composition, and a food composition.

[0071] The composition of the present invention can be any of an oral composition and a topical composition. It is considered that the Vaccinium uliginosum extract and the corn silk extract in the present invention are preferably absorbed through the digestive tract by oral ingestion, and their active ingredients exert effects in the body. Therefore, according to one preferred embodiment of the present invention, the composition of the present invention is an oral composition.

[0072] When the composition of the present invention is made into an oral composition, known ingredients (additives) incorporated in oral compositions can be further incorporated. There is no particular limitation on such ingredients, and examples thereof include emulsifiers, humectants, solvents, emollients, stabilizers, thickeners, preservatives, lubricants, chelating agents, fillers, excipients, powders, fragrances, flavoring agents, absorbents, dyes, opacifiers, antioxidants, preservatives, vitamins, amino acids, nutritional agents, minerals (electrolytes), flavoring agents such as synthetic flavoring agents and natural flavoring agents, pectic acid and its salts, alginic acid and its salts, organic acids, pH adjusters, glycerin, alcohols, carbonating agents used in carbonated beverages, etc.

[0073] The oral composition in the present invention can be any of liquid, semi-solid, and solid, without limitation, and is preferably a beverage.

[0074] When the composition of the present invention is made into a topical composition, known ingredients (additives) incorporated in topical compositions can be further incorporated. There is no limitation on such ingredients, and examples thereof include emulsifiers, humectants, solvents, emollients, stabilizers, thickeners, preservatives, lubricants, chelating agents, fillers, excipients, powders, fragrances, flavoring agents, absorbents, dyes, opacifiers, antioxidants, vitamins, amino acids, etc.

[0075] The topical composition in the present invention can be any of liquid, semi-solid, and solid.

[0076] Examples

[0077] Based on the following examples, the present invention will be specifically described, but the present invention is not limited to these examples. The content is expressed in mass% unless otherwise specified.

[0078] Evaluation of the anti-glycation effects of Vaccinium uliginosum extract and corn silk extract

[0079] Using a collagen anti-glycation analysis kit (manufactured by COSMO BIO COMPANY, LIMITED), a comparative study was conducted on the addition of Vaccinium uliginosum extract and / or corn silk extract and the non-addition of Vaccinium uliginosum extract and / or corn silk extract to evaluate the anti-glycation effect. As the Vaccinium uliginosum extract,

[0080] Heilongjiang Shangzhi Lvye Berry Co., Ltd.

[0081] The manufactured Vaccinium uliginosum juice (Brix: 65). As the corn silk extract, the dried corn silk extract (extract without excipients) manufactured by Fukudaryu Co., Ltd. was used. Under ice-cold conditions, the neutralized collagen solution was injected into a 96-well plate (Bottom Clear type) at 50 μl / well, and left to gel overnight in a 37°C incubator. A 200 mM fructose solution of 50 μl / well was spread on the collagen gel. Thereafter, a 20 mM aminoguanidine (AG) solution was used as a positive control, and Vaccinium uliginosum extracts and / or corn silk extracts with different concentrations were added, stirred with a plate mixer, then left to stand in a 37°C incubator for 0 to 35 days, and then the fluorescence intensity (excitation wavelength 370 nm, fluorescence wavelength 440 nm) was measured, and the glycation inhibition rate (%) was calculated based on each fluorescence intensity. The glycation inhibition rate is denoted as the value obtained according to the calculation formula of 100 - 100(sample fluorescence intensity) / (control fluorescence intensity).

[0082] The evaluation results of the anti-glycation effects after 28 days when Vaccinium uliginosum extract or corn silk extract was added alone are shown in Figure 1 and the evaluation results of the anti-glycation effects after 35 days are shown in Figure 2 . A concentration-dependent anti-glycation effect was confirmed in both Vaccinium uliginosum extract and corn silk extract.

[0083] Next, the evaluation results of the anti-glycation effects after 28 days when Vaccinium uliginosum extract and corn silk extract were added in combination are shown in Table 1, and the evaluation results of the anti-glycation effects after 35 days are shown in Table 2.

[0084] [Table 1]

[0085] Table 1: Evaluation results of the anti-glycation effects after 28 days

[0086]

[0087] [Table 2]

[0088] Table 2: Evaluation results of the anti-glycation effects after 35 days

[0089]

[0090] Based on the above results, it is shown that when the concentration ratio of Vaccinium uliginosum extract (Vaccinium uliginosum juice with Brix 65) to corn silk extract is in the range of 4:1 to 1:2, a synergistic effect is achieved in glycation inhibition.

Claims

1. A composition comprising Vaccinium uliginosum extract, wherein the Vaccinium uliginosum extract is used in combination with a composition comprising corn silk extract.

2. A composition comprising corn silk extract, wherein the corn silk extract is used in combination with a composition comprising Vaccinium uliginosum extract.

3. A composition comprising Vaccinium uliginosum extract and corn silk extract.

4. The composition according to any one of claims 1 to 3, which is used for inhibiting glycation.

5. The composition according to any one of claims 1 to 3, which is used for inhibiting glycation of the skin.

6. The composition according to any one of claims 1 to 3, which is used for preventing or improving one or more selected from the group consisting of firmness, wrinkles, and sagging.

7. The composition according to any one of claims 1 to 3, which is used in such a manner that CA / CB becomes 0.15 to 7.5, wherein, Let the dry weight of the corn silk extract be CA and the dry weight of the Vaccinium uliginosum extract be CB.

8. The composition according to any one of claims 1 to 3, which is an oral composition.

Images